A carregar...
EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
BRAF(V600E) is the most common oncogenic lesion in melanoma and results in constitutive activation of the mitogen-activated protein kinase (MAPK) pathway and uncontrolled cell growth. Selective BRAF inhibitors such as vemurafenib have been shown to neutralize oncogenic signaling, restrain cellular g...
Na minha lista:
| Publicado no: | Cancer Discov |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4355085/ https://ncbi.nlm.nih.gov/pubmed/25542448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0295 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|